Dr. Matthew Meyerson MD, PhD

Matthew Meyerson joins Isabl as Chairman of the Scientific Advisory Board

Isabl is pleased to announce that Matthew Meyerson, MD, PhD has joined the company as the Chair of the Scientific Advisory Board. Dr. Meyerson is an internationally recognized thought leader in the field of cancer genomics and was co-founder of Foundation Medicine. He is currently the Director of the Center for Cancer Genomics at Dana-Farber Cancer Institute, and Professor of Genetics and Medicine at Harvard Medical School.

Dr. Meyerson’s research has used genomics to discover the causes of and identify potential therapeutic approaches for cancer. His laboratory has made seminal discoveries of cancer-causing mutations in a variety of cancer types, and has identified potential therapeutic opportunities and mechanisms of resistance relevant to cancer treatment. Dr. Meyerson has also helped lead large national cancer genomic efforts, including The Cancer Genome Atlas project (TCGA). Dr. Meyerson has received many awards in recognition of his accomplishments in cancer genomics, such as election to the National Academy of Medicine and being named the second most influential scientist across all scientific fields by Thomson Reuters.

“Clinical cancer genomics has made great strides using targeted panels, but we are still missing what happens in 99% of the genome. Moving to whole genome and whole transcriptome sequencing will allow us to find all the key alterations in cancer genomes and help us identify more opportunities for patient tailored therapy,” said Dr. Meyerson.

“We are pleased to have Dr. Meyerson’s leadership on our SAB, and his partnership toward our shared vision of bringing complete genomic characterization to the clinic,” said Dr. Elli Papaemmanuil, CEO of Isabl. “Matthew understands the unmet clinical need, how cancer whole genome and transcriptome analysis uniquely fulfills the promise of patient tailored medicine and what it takes to bring a state of the art research assay into standard of care.”

--

--

--

Isabl improves cancer diagnosis and biomarker discovery by integrating whole genome and transcriptome sequencing.

Love podcasts or audiobooks? Learn on the go with our new app.

Recommended from Medium

Here Is Why You Did Not See Astrologers Predicting Pandemic

Einstein & General Relativity

“A Pretty Wild Idea”

The world’s First ‘Living Robots’-Xenobot

Bizarre Half-Male, Half-Female Bird Discovered In Pennsylvania

Graphene: The Miracle Material

Should We Trust Our Future to AI Scientists?

We don’t understand entanglement

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Isabl Inc.

Isabl Inc.

Isabl improves cancer diagnosis and biomarker discovery by integrating whole genome and transcriptome sequencing.

More from Medium

Systemic entropy and evolution: re-evaluating Murphy’s Law

Impact of Various Factors on Asthma Rates in the United States

6 Ways to Celebrate the Holidays When You’re Living Alone

We can’t let the Mountain Equipment Co-op story repeat itself